US › Healthcare

Cognition Therapeutics Inc (CGTX)

US · Healthcare · Biotechnology

$1.06+3.92%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-3.9M

EPS

$-0.04

EPS estimate

$-0.06

EPS came in at -0.04 against a street estimate of -0.06 — a beat of 33.3%.

Key statistics

Market cap

$93.5M

Forward P/E

0.0

P/B

2.85

Book value

$0.35

EPS (TTM)

$-0.17

52-week high

$2.05

52-week low

$0.55

50-day MA

$1.01

200-day MA

$1.18

Beta

1.79

Analyst view

Analysts rate Cognition Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $3.33.

Shareholding

Insiders

1.29%

Institutions

23.78%

Largest institutional holders

Fund	Stake
BIOS CAPITAL MANAGEMENT, LP	6.31%
Davenport & Company LLC	4.48%
Vanguard Capital Management, LLC	3.16%
Renaissance Technologies Corp	1.18%
Chescapmanager LLC	1.05%
BlackRock Inc	1.02%
Geode Capital Management, LLC	0.97%
Hilton Capital Management, LLC	0.58%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cognition Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.